D&A at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
Depreciation expense was $1,812 and $1,135 in the three months ended June 30, 2026, and 2025, respectively. Intangible asset amortization expense was $62,953 and $55,473 in the three months ended June 30, 2026 and 2025, respectively. Depreciation expense was $2,275 and $2,226 in the six months ended June 30, 2026, and 2025, respectively. Intangible asset amortization expense was $118,426 and $110,946 in the six months ended June 30, 2026 and 2025, respectively.
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s D&A?
- Collegium Pharmaceutical, Inc. (COLL) reported D&A of $1.81M in Q2 2026.
- How has Collegium Pharmaceutical, Inc.'s D&A changed year-over-year?
- Collegium Pharmaceutical, Inc.'s D&A increased by 59.6% year-over-year, from $1.14M to $1.81M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s D&A?
- Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s D&A has grown at a 24.6% compound annual growth rate (CAGR), from $1.74M to $4.18M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Collegium Pharmaceutical, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
